Biomarkers of Neurodegeneration Elevated in Hospitalized Covid-19 Patients
Some even higher than levels found in Alzheimer’s patients
Read More
Author: Mukuntha Subburayan
Covid-19: Virus During Pregnancy Increases Birth Complication Risk
Two new studies strengthen link between SARS-CoV-2 infection and poor outcomes
Read More
ASH 2021: A Focus on Leukemia & Lymphoma
Focus on Lymphoma Leukemia
Read More
#PWChat: The #ThisIsOurShot Campaign – Part 1
The latest installment of the #PWChat series centered around the #ThisIsOurShot campaign, a...
Read MoreValbenazine for Tardive Dyskinesia Demonstrates Robust & Long-Term Improvement
Chirag Shah, PharmD Head, Strategic Publications & Medical Education Medical Affairs, Neurocrine Biosciences, Inc. “In clinical trials for valbenazine, approved for treating tardive dyskinesia (TD)—a persistent and...
Read MoreSix Best Practices for Telepsychiatry and Tardive Dyskinesia
In July 2020, experts participated in individual semi-structured qualitative interviews about how tardive Dyskinesia (TD) is diagnosed and treated in real-world settings. A virtual roundtable follow-up was conducted in November...
Read MoreAPA 2021: Does Cognitive Behavioral Therapy Impact Dementia?
Researchers presented the findings of cognitive behavioral therapy (CBT) benefits on anxiety, depression, and quality of life in patients with mild cognitive impairment (MCI) and dementia “Today, no reviews have analyzed...
Read MorePW Podcast: History of Vaccines; AACR 2021 Highlights; Empathy & Bedside Manner
Episode Segments Physician’s Weekly correspondents: Rachel Giles, MD, PhD, Medicom Medical Publishers Peter Hofland, PhD, Sunvalley Communication Paul Schmidt, Sunvalley Communication ...
Read MoreMany Psychiatrists Incorrectly Treating Tardive Dyskinesia
By: Chirag Shah; Shereta Wiley; Sylvie Stacy; Leslie Lundt In a poster session, researchers sought to understand the evolving continuing medical education (CME) needs of psychiatrists managing patients with tardive dyskinesia...
Read MoreAPA 2021: Is Aripiprazole-Induced Tardive Dyskinesia an Unrecognized Threat?
As an involuntary movement disorder resulting from exposure to dopamine antagonists, tardive dyskinesia (TD) classically manifests as involuntary oro-bucco-lingual and facial dyskinesia, as well as limb, trunk, and respiratory...
Read MoreInnovative Psychopharmacology in Treatment-Refractory Patients
There is growing number of treatment-refractory patients in psychiatric practice. Although evidence-based treatments may be effective in most patients, there is a significant number of psychiatric patients, who may not have an...
Read MoreImpact of Tardive Dyskinesia on Physical Ability, Social Functioning, and Overall Health
Data from the real-world RE-KINECT study were analyzed to better understand the impact of tardive dyskinesia (TD) on wellbeing and health state in patients who are aware of their TD. Over 200 adults with over 3 months of...
Read More
American Psychiatric Association 2021 Kicks Off: May 1-3
This Year’s Theme: Finding Equity Through Advances in Mind & Brain in Unsettled Times...
Read MoreAPA 2021: Explore Sessions on COVID-19
A year since COVID-19 was declared a worldwide emergency, experts warn that a subsequent mental health pandemic is imminent, due to the lasting adverse impacts of stress, anxiety and isolation. This year’s Annual Meeting offers...
Read MoreAPA 2021 Schedule at a Glance
Friday, April 30, 2021 11:00 a.m. – 5:30 p.m. ET Pre-Conference Expo Virtual Exhibit Gallery Product Theater Showcases Saturday, May 1, 2021 10:00 a.m. – 11:00 a.m. ET Opening Session (Plenary), Featuring Keynote Speaker Isabel...
Read More